
Hirotaka Shibata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/720801/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparison and commutability study between standardized liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) and chemiluminescent enzyme immunoassay for aldosterone measurement in blood. Endocrine Journal, 2022, 69, 45-54.	1.6	16
2	Annual reports on hypertension research 2020. Hypertension Research, 2022, 45, 15-31.	2.7	7
3	Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials. Hypertension Research, 2022, 45, 210-220.	2.7	37
4	Excretion Patterns of Urinary Sediment and Supernatant Podocyte Biomarkers in Patients with CKD. Kidney360, 2022, 3, 63-73.	2.1	6
5	Adrenal Vein Sampling With Gadolinium Contrast Medium in a Patient With Florid Primary Aldosteronism and Iodine Allergy. Journal of the Endocrine Society, 2022, 6, bvac007.	0.2	2
6	Optimal blood pressure target to prevent severe hypertension in pregnancy: A systematic review and meta-analysis. Hypertension Research, 2022, 45, 887-899.	2.7	14
7	Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients. Metabolites, 2022, 12, 147.	2.9	3
8	Renoprotective effect of additional sodium–glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function. Journal of Diabetes Investigation, 2022, 13, 1330-1338.	2.4	2
9	Re-Assessment of the Oral Salt Loading Test Using a New Chemiluminescent Enzyme Immunoassay Based on a Two-Step Sandwich Method to Measure 24-Hour Urine Aldosterone Excretion. Frontiers in Endocrinology, 2022, 13, 859347.	3.5	5
10	Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocrine Journal, 2022, 69, 327-359.	1.6	67
11	Comprehensive lipidomics of lupusâ€prone mice using <scp>LC–MS</scp> / <scp>MS</scp> identifies the reduction of palmitoylethanolamide that suppresses <scp>TLR9</scp> â€mediated inflammation. Genes To Cells, 2022, , .	1.2	2
12	Update on Hypertension Research in 2021. Hypertension Research, 2022, 45, 1276-1297.	2.7	13
13	Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab. CEN Case Reports, 2021, 10, 35-41.	0.9	7
14	CASZ1b is a novel transcriptional corepressor of mineralocorticoid receptor. Hypertension Research, 2021, 44, 407-416.	2.7	10
15	Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism. Hypertension Research, 2021, 44, 464-472.	2.7	29
16	<i>α</i> â€Tocopherol suppresses hepatic steatosis by increasing CPTâ€1 expression in a mouse model of dietâ€induced nonalcoholic fatty liver disease. Obesity Science and Practice, 2021, 7, 91-99.	1.9	8
17	Diverse pathological lesions of primary aldosteronism and their clinical significance. Hypertension Research, 2021, 44, 498-507.	2.7	5
18	Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists. Journal of the Endocrine Society, 2021, 5, bvab020.	0.2	5

#	Article	IF	CITATIONS
19	Development of a New Chemiluminescent Enzyme Immunoassay Using a Two-Step Sandwich Method for Measuring Aldosterone Concentrations. Diagnostics, 2021, 11, 433.	2.6	17
20	Effectiveness of subcutaneous tocilizumab in refractory adult Still's disease: report of three cases and a review of the literature. Modern Rheumatology Case Reports, 2021, 5, 365-370.	0.7	1
21	Factors Influencing Plasma Coproporphyrin†Concentration as Biomarker of OATP1B Activity in Patients With Rheumatoid Arthritis. Clinical Pharmacology and Therapeutics, 2021, 110, 1096-1105.	4.7	7
22	Exosomes and exosomal cargo in urinary extracellular vesicles: novel potential biomarkers for mineralocorticoid-receptor-associated hypertension. Hypertension Research, 2021, 44, 1668-1670.	2.7	4
23	A Case of Nephrotic Syndrome Associated with Buerger's Disease. Internal Medicine, 2021, , .	0.7	Ο
24	Dopamine-Secreting Pheochromocytoma and Paraganglioma. Journal of the Endocrine Society, 2021, 5, bvab163.	0.2	11
25	Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control. Scientific Reports, 2021, 11, 21931.	3.3	1
26	A case of polyneuropathy associated with diabetic ketoacidosis in newâ€onset type 1 diabetes. Journal of Diabetes Investigation, 2021, , .	2.4	1
27	A case of denosumab-associated membranous nephropathy in a patient with rheumatoid arthritis. CEN Case Reports, 2020, 9, 1-5.	0.9	3
28	Clinical and genetic analysis in a family with familial renal glucosuria: Identification of an N101K mutation in the sodium–glucose cotransporterÂ2 encoded by a solute carrier familyÂ5 memberÂ2 gene. Journal of Diabetes Investigation, 2020, 11, 573-577.	2.4	7
29	Historical changes and between-facility differences in adrenal venous sampling for primary aldosteronism in Japan. Journal of Human Hypertension, 2020, 34, 34-42.	2.2	8
30	Oral Salt Loading Test is Associated With 24-Hour Blood Pressure and Organ Damage in Primary Aldosteronism Patients. Journal of the Endocrine Society, 2020, 4, bvaa116.	0.2	2
31	Suspected Borderline Aldosteronism in Hypertension. Journal of the American College of Cardiology, 2020, 76, 759-760.	2.8	3
32	Urinary podocyte mRNAs precede microalbuminuria as a progression risk marker in human type 2 diabetic nephropathy. Scientific Reports, 2020, 10, 18209.	3.3	17
33	Supplementation of branched-chain amino acids decreases fat accumulation in the liver through intestinal microbiota-mediated production of acetic acid. Scientific Reports, 2020, 10, 18768.	3.3	31
34	Discrepancy Between Fasting Flow-Mediated Dilation and Parameter of Lipids in Blood: A Randomized Exploratory Study of the Effect of Omega-3 Fatty Acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia. Advances in Therapy, 2020, 37, 2169-2183.	2.9	1
35	Sensitive and selective quantification of mid-regional proadrenomedullin in human plasma using ultra-performance liquid chromatography coupled with tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2020, 183, 113168.	2.8	2
36	A case of adrenaline-predominant paraganglioma diagnosed with a state of shock after glucagon injection. Hypertension Research, 2020, 43, 473-475.	2.7	3

#	Article	IF	CITATIONS
37	Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 674-675.	0.9	16
38	III. Hypokalemia and Endocrine Disorders. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 718-726.	0.0	0
39	Endocrine Diseases which are Suspected by Electrolyte Disorders. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 703-704.	0.0	Ο
40	<scp>l</scp> -Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of rapamycin complex 1 signaling. Modern Rheumatology, 2019, 29, 885-891.	1.8	17
41	Synonymous but Not Silent: A Synonymous VHL Variant in Exon 2 Confers Susceptibility to Familial Pheochromocytoma and von Hippel-Lindau Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3826-3834.	3.6	17
42	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertension Research, 2019, 42, 1235-1481.	2.7	1,047
43	Pubertal and Adult Testicular Functions in Nonclassic Lipoid Congenital Adrenal Hyperplasia: A Case Series and Review. Journal of the Endocrine Society, 2019, 3, 1367-1374.	0.2	12
44	Predictors of Clinical Success After Surgery for Primary Aldosteronism in the Japanese Nationwide Cohort. Journal of the Endocrine Society, 2019, 3, 2012-2022.	0.2	24
45	Relationships between computed tomography-assessed density, abdominal fat volume, and glucose metabolism after sleeve gastrectomy in Japanese patients with obesity. Endocrine Journal, 2019, 66, 605-613.	1.6	7
46	High Prevalence of Diabetes in Patients With Primary Aldosteronism (PA) Associated With Subclinical Hypercortisolism and Prediabetes More Prevalent in Bilateral Than Unilateral PA: A Large, Multicenter Cohort Study in Japan. Diabetes Care, 2019, 42, 938-945.	8.6	70
47	Effects of Sleeve Gastrectomy on Blood Pressure and the Renal Renin–Angiotensin System in Rats with Dietâ€Induced Obesity. Obesity, 2019, 27, 785-792.	3.0	5
48	Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism. Hypertension Research, 2019, 42, 817-824.	2.7	29
49	Dr. Maeshima, <i>et al,</i> reply. Journal of Rheumatology, 2019, 46, 655-656.	2.0	Ο
50	Impact of adrenocorticotropic hormone stimulation during adrenal venous sampling on outcomes of primary aldosteronism. Journal of Hypertension, 2019, 37, 1077-1082.	0.5	24
51	Influence of antihypertensive drugs in the subtype diagnosis of primary aldosteronism by adrenal venous sampling. Journal of Hypertension, 2019, 37, 1493-1499.	0.5	9
52	Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism. Journal of Hypertension, 2019, 37, 1513-1520.	0.5	44
53	An Adult Fatal Case with a <i>STAT1</i> Gain-of-function Mutation Associated with Multiple Autoimmune Diseases. Journal of Rheumatology, 2019, 46, 325-327.	2.0	15
54	2. Diagnosis and Treatment of Endocrine Hypertension. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 452-459.	0.0	0

#	Article	IF	CITATIONS
55	Accuracy of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of aldosterone in primary aldosteronism. Clinical Endocrinology, 2018, 88, 645-651.	2.4	57
56	Significance of Computed Tomography and Serum Potassium in Predicting Subtype Diagnosis of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 900-908.	3.6	70
57	Epidermal growth factor receptor/extracellular signal-regulated kinase pathway enhances mineralocorticoid receptor transcriptional activity through protein stabilization. Molecular and Cellular Endocrinology, 2018, 473, 89-99.	3.2	12
58	Granulomatous interstitial nephritis associated with silica. Nephrology, 2018, 23, 190-190.	1.6	1
59	Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism. Hypertension, 2018, 71, 530-537.	2.7	144
60	Development and validation of subtype prediction scores for the workup of primary aldosteronism. Journal of Hypertension, 2018, 36, 2269-2276.	0.5	49
61	Bioelectrical Impedance Analysis Results for Estimating Body Composition Are Associated with Glucose Metabolism Following Laparoscopic Sleeve Gastrectomy in Obese Japanese Patients. Nutrients, 2018, 10, 1456.	4.1	13
62	Clinical Characteristics and Postoperative Outcomes of Primary Aldosteronism in the Elderly. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3620-3629.	3.6	33
63	Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4456-4464.	3.6	48
64	Intestinal Mineralocorticoid Receptor Contributes to Epithelial Sodium Channel–Mediated Intestinal Sodium Absorption and Blood Pressure Regulation. Journal of the American Heart Association, 2018, 7,	3.7	26
65	Correlation Between Lateralization Index of Adrenal Venous Sampling and Standardized Outcome in Primary Aldosteronism. Journal of the Endocrine Society, 2018, 2, 893-902.	0.2	29
66	The Occurrence of Apparent Bilateral Aldosterone Suppression in Adrenal Vein Sampling for Primary Aldosteronism. Journal of the Endocrine Society, 2018, 2, 398-407.	0.2	23
67	Successful treatment of a case of acute liver failure and disseminated intravascular coagulation induced by heat stroke with plasma exchange and continuous hemodiafiltration. Nihon Toseki Igakkai Zasshi, 2018, 51, 539-544.	0.1	0
68	Discussion on Clinical Pearl and Future Perspective of Clinical Practice of Endocrine Hypertension. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 720-730.	0.0	0
69	Endocrine Hypertension: Pearl and Pitfall in Daily Clinical Practice. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 655-658.	0.0	0
70	Large-vessel involvement in granulomatosis with polyangiitis successfully treated with rituximab: A case report and literature review. Modern Rheumatology, 2017, 27, 699-704.	1.8	10
71	Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27â^'IgDâ^' Cells. Journal of Immunology, 2017, 199, 425-434.	0.8	72
72	Glucagon-like peptide-1 reduces pancreatic β-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats. Scientific Reports, 2017, 7, 5578.	3.3	7

#	Article	IF	CITATIONS
73	Role of spleen-derived IL-10 in prevention of systemic low-grade inflammation by obesity [Review]. Endocrine Journal, 2017, 64, 375-378.	1.6	27
74	High Glucose Stimulates Mineralocorticoid Receptor Transcriptional Activity Through the Protein Kinase C β Signaling. International Heart Journal, 2017, 58, 794-802.	1.0	20
75	Adrenal Insufficiency under Standard Dosage of Glucocorticoid Replacement after Unilateral Adrenalectomy for Cushing's Syndrome. Case Reports in Endocrinology, 2016, 2016, 1-4.	0.4	0
76	Calibration and evaluation of routine methods by serum certified reference material for aldosterone measurement in blood. Endocrine Journal, 2016, 63, 1065-1080.	1.6	22
77	Fulminant typeÂ1 diabetes mellitus with antiâ€programmed cell deathâ€1 therapy. Journal of Diabetes Investigation, 2016, 7, 915-918.	2.4	139
78	The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1889-1916.	3.6	1,921
79	Pore alterations of the endothelial lining of rat fenestrated intestinal capillaries exposed to acute stress. Histology and Histopathology, 2016, 31, 807-17.	0.7	0
80	A Clinical Approach to Brown Adipose Tissue in the Para-Aortic Area of the Human Thorax. PLoS ONE, 2015, 10, e0122594.	2.5	13
81	GEMIN4 functions as a coregulator of the mineralocorticoid receptor. Journal of Molecular Endocrinology, 2015, 54, 149-160.	2.5	22
82	Distribution of histaminergic neuronal cluster in the rat and mouse hypothalamus. Journal of Chemical Neuroanatomy, 2015, 68, 1-13.	2.1	10
83	Mineralocorticoid Receptor-Associated Hypertension and Its Organ Damage: Clinical Relevance for Resistant Hypertension. American Journal of Hypertension, 2012, 25, 514-523.	2.0	103
84	Guidelines for the diagnosis and treatment of primary aldosteronism -The Japan Endocrine Society 2009 Endocrine Journal, 2011, 58, 711-721.	1.6	457
85	Coactivation of SF-1-Mediated Transcription of Steroidogenic Enzymes by Ubc9 and PIAS1. Endocrinology, 2011, 152, 2266-2277.	2.8	16
86	NF-YC Functions as a Corepressor of Agonist-bound Mineralocorticoid Receptor. Journal of Biological Chemistry, 2010, 285, 8084-8093.	3.4	31
87	Coactivation of the N-terminal Transactivation of Mineralocorticoid Receptor by Ubc9. Journal of Biological Chemistry, 2007, 282, 1998-2010.	3.4	74
88	Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription. Journal of Biological Chemistry, 2005, 280, 6721-6730.	3.4	45
89	FHL2, UBC9, and PIAS1 are Novel Estrogen Receptor αâ€Interacting Proteins. Endocrine Research, 2004, 30, 617-621.	1.2	41
90	Proteasomeâ€Mediated Mineralocorticoid Receptor Degradation Attenuates Transcriptional Response to Aldosterone. Endocrine Research, 2004, 30, 611-616.	1.2	29

#	Article	IF	CITATIONS
91	COUPâ€TF and Transcriptional Coâ€Regulators in Adrenal Steroidogenesis. Endocrine Research, 2004, 30, 795-801.	1.2	16
92	Regulation of differential COUP-TF-coregulator interactions in adrenal cortical steroidogenesis. Journal of Steroid Biochemistry and Molecular Biology, 2003, 85, 449-456.	2.5	34
93	Nuclear Receptors and Co-Regulators in Adrenal Tumors. Hormone Research in Paediatrics, 2003, 59, 85-93.	1.8	8
94	A RING-FINGER PROTEIN CIP-2 IS A NOVEL REGULATOR OF COUP-TF ACTION IN THE ADRENAL CORTEX. Endocrine Research, 2002, 28, 581-581.	1.2	6
95	Expression and regulation of nuclear receptor coactivators in glucocorticoid action. Molecular and Cellular Endocrinology, 2002, 189, 181-189.	3.2	50
96	Expression Profiles of COUP–TF, DAX-1, and SF-1 in the Human Adrenal Gland and Adrenocortical Tumors: Possible Implications in Steroidogenesis. Molecular Genetics and Metabolism, 2001, 74, 206-216.	1.1	63
97	Orphan Receptors Coup-TF and Dax-1 as Targets in Disordered CYP17 Expression in Adrenocortical Tumors. Endocrine Research, 2000, 26, 1039-1044.	1.2	13
98	Transcriptional Regulation of Steroid Receptor Coactivator-1 (SRC-1) in Glucocorticoid Action. Endocrine Research, 2000, 26, 1033-1038.	1.2	14
99	Risk Factors Associated with Persistent Postoperative Hypertension in Cushing's Syndrome. Endocrine Research, 2000, 26, 791-795.	1.2	16
100	Differential expression of an orphan receptor coup-tfi and corepressors in adrenal tumors. Endocrine Research, 1998, 24, 881-885.	1.2	14
101	COUP-TFI Expression in Human Adrenocortical Adenomas: Possible Role in Steroidogenesis. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4520-4520.	3.6	25
102	The possible role of apoptosis-suppressing genes, BCL-2 and MCL-1/EAT in human adrenal tumors. Endocrine Research, 1998, 24, 955-960.	1.2	13
103	Gene Silencing by Chicken Ovalbumin Upstream Promoter-Transcription Factor I (COUP-TFI) Is Mediated by Transcriptional Corepressors, Nuclear Receptor-Corepressor (N-CoR) and Silencing Mediator for Retinoic Acid Receptor and Thyroid Hormone Receptor (SMRT). Molecular Endocrinology, 1997, 11, 714-724.	3.7	149
104	Gene Silencing by Chicken Ovalbumin Upstream Promoter-Transcription Factor I (COUP-TFI) Is Mediated by Transcriptional Corepressors, Nuclear Receptor-Corepressor (N-CoR) and Silencing Mediator for Retinoic Acid Receptor and Thyroid Hormone Receptor (SMRT). Molecular Endocrinology, 1997, 11, 714-724.	3.7	65
105	Modulation of Angiotensin II Type 1 Receptor mRNA Expression in Human Blood Cells: Comparison of Platelets and Mononuclear Leucocytes Endocrine Journal, 1995, 42, 15-22.	1.6	30
106	Significance of steroidogenic enzymes in the pathogenesis of hyperfunctioning and non-hyperfunctioning adrenal tumor. Steroids, 1995, 60, 42-47.	1.8	25
107	Gene Expression of Angiotensin II Receptor in Blood Cells of Cushing's Syndrome. Hypertension, 1995, 26, 1003-1010.	2.7	21
108	Steroid Contents and Cortical Steroidogenic Enzymes in Non-Hyperfunctioning Adrenal Adenoma Endocrine Journal, 1994, 41, 267-274.	1.6	15

#	Article	IF	CITATIONS
109	Significance of steroidogenic enzymes in the pathogenesis of adrenal tumour. European Journal of Endocrinology, 1993, 128, 235-242.	3.7	36